← Back to Screener
EyePoint, Inc. Common Stock (EYPT)
Price$15.07
Favorite Metrics
Price vs S&P 500 (26W)1.27%
Price vs S&P 500 (4W)3.36%
Market Capitalization$1.26B
All Metrics
Book Value / Share (Quarterly)$3.70
P/TBV (Annual)1.24x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-8.83%
Cash Flow / Share (Quarterly)$-2.94
Price vs S&P 500 (YTD)-22.42%
Gross Margin (TTM)93.41%
Net Profit Margin (TTM)-739.39%
EPS (TTM)$-3.16
10-Day Avg Trading Volume0.85M
EPS Excl Extra (TTM)$-3.16
Revenue Growth (5Y)-1.85%
EPS (Annual)$-3.17
ROI (Annual)-75.78%
Gross Margin (Annual)93.41%
Net Profit Margin (5Y Avg)-320.16%
Cash / Share (Quarterly)$3.70
Revenue Growth QoQ (YoY)-94.65%
ROA (Last FY)-63.73%
Revenue Growth TTM (YoY)-27.50%
EBITD / Share (TTM)$-3.29
ROE (5Y Avg)-55.80%
Operating Margin (TTM)-775.96%
Cash Flow / Share (Annual)$-2.94
P/B Ratio4.11x
P/B Ratio (Quarterly)4.94x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)36.83x
Net Interest Coverage (TTM)-95.46x
ROA (TTM)-72.52%
EV / EBITDA (TTM)176.68x
EPS Incl Extra (Annual)$-3.17
Current Ratio (Annual)8.88x
Quick Ratio (Quarterly)8.28x
3-Month Avg Trading Volume1.27M
52-Week Price Return169.01%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.83
P/S Ratio (Annual)40.08x
Asset Turnover (Annual)0.09x
52-Week High$19.11
Operating Margin (5Y Avg)-333.51%
EPS Excl Extra (Annual)$-3.17
CapEx CAGR (5Y)55.57%
Tangible BV CAGR (5Y)35.00%
26-Week Price Return10.02%
Quick Ratio (Annual)8.28x
13-Week Price Return-6.22%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.88x
Enterprise Value$1,155.499
Revenue / Share Growth (5Y)-30.71%
Asset Turnover (TTM)0.10x
Book Value / Share Growth (5Y)29.31%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.00x
Pretax Margin (Annual)-738.53%
Cash / Share (Annual)$3.70
3-Month Return Std Dev71.07%
Gross Margin (5Y Avg)86.50%
Net Income / Employee (TTM)$-1
ROE (Last FY)-75.78%
Net Interest Coverage (Annual)-27.76x
EPS Basic Excl Extra (Annual)$-3.17
P/FCF (TTM)22.20x
Receivables Turnover (TTM)49.88x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.16
Receivables Turnover (Annual)49.87x
ROI (TTM)-88.31%
P/S Ratio (TTM)40.08x
Pretax Margin (5Y Avg)-319.91%
Revenue / Share (Annual)$0.43
Tangible BV / Share (Annual)$2.83
Price vs S&P 500 (52W)133.91%
Year-to-Date Return-18.28%
5-Day Price Return2.82%
EPS Normalized (Annual)$-3.17
ROA (5Y Avg)-38.76%
Net Profit Margin (Annual)-739.42%
Month-to-Date Return15.83%
Cash Flow / Share (TTM)$-2.64
EBITD / Share (Annual)$-3.29
Operating Margin (Annual)-775.98%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-48.55%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.16
P/TBV (Quarterly)1.24x
P/B Ratio (Annual)4.94x
Inventory Turnover (TTM)1.00x
Pretax Margin (TTM)-738.50%
Book Value / Share (Annual)$3.70
Price vs S&P 500 (13W)-9.08%
Beta1.83x
P/FCF (Annual)124.00x
Revenue / Share (TTM)$0.38
ROE (TTM)-88.31%
52-Week Low$5.30
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.28
4.28
4.28
4.28
Industry Peers — Lab Analytical Instruments(22)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
EYPTEyePoint, Inc. Common Stock | 40.08x | -1.85% | 93.41% | -775.96% | $15.07 |
AAgilent Technologies Inc. | 4.83x | 5.41% | 52.60% | 20.40% | $120.96 |
WATWaters Corp | 10.18x | 6.00% | 59.28% | 25.36% | $335.61 |
MTDMettler-Toledo International | 6.66x | 5.47% | 59.37% | 26.05% | $1324.66 |
ILMNIllumina Inc | 4.69x | 6.04% | 66.61% | 18.44% | $132.86 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $93.03 |
BIOBio-Rad Laboratories, Inc.Class A | 3.17x | 0.29% | 52.01% | 1.59% | $303.34 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.17x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRBruker Corporation | 1.81x | 11.57% | 47.13% | 1.40% | $41.10 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.81x | 11.57% | 47.13% | 1.40% | $320.13 |
AVTRAvantor, Inc. | 0.88x | 0.49% | 32.65% | -3.83% | $8.50 |
About
EyePoint Inc is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious retinal diseases, with the goal of improving patient outcomes while reducing treatment burden and follow-up care frequency. Its pipeline includes DURAVYU, a sustained-release product candidate for retinal diseases, and EYP-2301, an early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting vascular stability in conditions like wet age-related macular degeneration.